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Protein farnesylation is required for the activation of multiple proteins involved in cell diﬀerentiation and function. In white
adipose tissue protein, farnesylation has shown to be essential for the successful diﬀerentiation of preadipocytes into adipocytes.
We hypothesize that protein farnesylation is required for PPARγ2 expression and activation, and therefore for the diﬀerentiation
of human mesenchymal stem cells (MSCs) into adipocytes. MSCs were plated and induced to diﬀerentiate into adipocytes for
three weeks. Diﬀerentiating cells were treated with either an inhibitor of farnesylation (FTI-277) or vehicle alone. The eﬀect of
inhibition of farnesylation in diﬀerentiating adipocytes was determined by oil red O staining. Cell survival was quantiﬁed using
MTS Formazan. Additionally, nuclear extracts were obtained and prelamin A, chaperon protein HDJ-2, PPARγ, and SREBP-1
were determined by western blot. Finally, DNA binding PPARγ activity was determined using an ELISA-based PPARγ activation
quantiﬁcation method. Treatment with an inhibitor of farnesylation (FTI-277) arrests adipogenesis without aﬀecting cell survival.
This eﬀect was concomitant with lower levels of PPARγ expression and activity. Finally, accumulation of prelamin A induced an
increased proportion of mature SREBP-1 which is known to aﬀect PPARγ activity. In summary, inhibition of protein farnesylation
arrests the adipogenic diﬀerentiation of MSCs and aﬀects PPARγ expression and activity.
Copyright © 2007 Daniel Rivas et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
A common phenomenon seen during the normal aging pro-
cess is the redistribution of fat which accumulates in usually
non-fat tissues [1–4]. Several hypotheses have been tested to
explain age-related fat accumulation outside adipose tissue
including a possible reduction in the capacity to metabolize
fatty acids [5], a predominance of lipodystrophy [6], or ﬁ-
nally a pure process of dediﬀerentiation of nonadipose mes-
enchymal stem cell (MSCs) into adipocytes-like cells [6–8].
Indeed, bone is not the exception to this phenomenon.
One of the characteristics of senile osteoporosis is the pre-
dominance of adipose tissue within the bone marrow asso-
ciated with a signiﬁcant reduction in osteoblastogenesis and
thusinboneformation[4,9].Thepredominanceofadipoge-
nesis seen in aging bone is the consequence of mesenchymal
stem cells “dediﬀerentiation” which induces them to remain
in a preadipocytic stage [7, 10].
There is evidence that among the multiple mechanisms
involved in adipogenesis, protein farnesylation is essential
for the diﬀerentiation of white fat precursors into mature
adipocytes [11]. When human preadipocytes were induced
to diﬀerentiate in the presence of insulin, addition of in-
hibitors of farnesylation aﬀectedtheir diﬀerentiation and de-
creased peroxisome proliferator activator gamma (PPARγ)
expression [11]. Therefore, it is tempting to propose that, as
in white fat, protein farnesylation could be necessary for the
successful diﬀerentiation of MSCs into adipocytes within the
bone marrow.
Lamin A is an example of a protein that not only requires
farnesylation to be activated [12] but also plays an important
role in adipogenesis [13]. Lamin A belongs to the group of
proteins that form the lamina which keeps the nuclear en-
velope playing a role in a number of nuclear processes in-
cluding DNA replication and cell diﬀerentiation [12, 14]. Al-
terations in lamin A activation as well as mutations in the2 PPAR Research
lamin A encoding gene are known as “laminopathies.” In hu-
mans, lamins have been linked to Familial partial lipodystro-
phy (FPLD) a disease that is characterized by adipose tissue
repartitioning with multiple metabolic disturbances, includ-
ing insulin resistance and dyslipidemia [15]. Lamins have
also been associated with other type of lipodystrophies such
asDunnigan-typeFamilialpartiallipodystrophy[13].Dueto
the fact that all these models of lamin A mutations aﬀect adi-
pogenesis and in some cases PPARγ expression and activity
[13, 15], we hypothesize that protein farnesylation in general
and lamin A farnesylation in particular could be required for
adipogenesis in a model of adipogenic diﬀerentiating mes-
enchymal stem cells (MSCs). In summary, the determination
of the potential eﬀect that protein farnesylation has on adi-
pogenesis and PPARγ expression in the bone marrow could
oﬀer a new approach to the understanding of the pathophys-
iology and treatment of senile osteoporosis.
2. MATERIALS AND METHODS
Reagents
FTase inhibitor-277 (FTI-277) was purchased from Sigma-
Aldrich Corporation (St. Louis, Mo, USA). FTI-277 was dis-
solvedinDimethylsulphoxideandthenﬁlter-sterilizedusing
a0 . 2μm ﬁlter. Other reagents were from Sigma-Aldrich Cor-
poration unless stated otherwise.
InvitroDifferentiationofMSCs
Human MSCs (BioWhittaker, Walkersville, Md, USA) were
induced to diﬀerentiate into adipocytes as previously de-
scribed [16]. Brieﬂy, MSCs were plated at a density of 5
× 105 cells per well in 100cm2 dishes containing MSCs
growth media (BioWhittaker, Walkersville, Md, USA) with
10% fetal calf serum (FCS) and incubated at 37
◦Cf o r2 4
hours. After the cells reached 60% conﬂuence, media were
replaced with MSCs growth media or induced to diﬀeren-
tiate into adipocytes using adipogenesis induction media
(AIM) (prepared with DMEM, 4.5g/L glucose, 1μMd e x a m -
ethasone, 0.2mM indomethacin, 1.7μM insulin, 0.5mM 3-
isobutyl-1-methylxanthine,10% FCS, 0.05U/mL penicillin,
and 0.05μg/mL streptomycin) for 3 days, incubated 3 days
in adipogenesis maintenance medium (DMEM, 4.5g/L glu-
cose, 1.7μM insulin, 10% FBS, 0.05U/mL penicillin, and
0.05μg/mL streptomycin), and then switched to induction
media again to promote adipogenic phenotype as previously
described[16].Inallexperiments,mediawerechangedevery
three days.
IdentiﬁcationoftheeffectofFTI-277onadipocyte
differentiation
MSCs were plated in 4cm2 dishes in a density of 4 × 104
cells per dish. At 60% conﬂuence, media were replaced with
AIM containing either FTI-277 (5–10μM) or vehicle alone.
At timed intervals (weeks 1, 2, and 3), media were aspi-
rated and cells were stained for oil red O and counterstained
with hematoxylin. Diﬀerentiated adipocytes were consid-
ered those polygonal in shape, with eccentrically located
nuclei, considerable cytoplasm, and lipid droplets scattered
throughout.
Identiﬁcationofnuclearblebbingusing
PropidiumIodideStaining
Cells were plated in 6-well plates, induced to diﬀerentiate,
and treated as previously described. After 2 weeks of diﬀer-
entiation and treatment, cells were ﬁxed using 70% ethanol
for 20 minutes. After thorough washing in PBS, cells were
stained for nuclear red ﬂuorescence using propidium iodide.
Nuclei were then observed via UV lightusing an Olympus
IX-70 microscope (Olympus, London, UK). Cells showing
deformities in the nuclear shape or vacuolization were con-
sidered positive for blebbing as previously described [17].
MeasurementofviablecellsaftertreatmentwithFTI-277
MSCs were seeded at a density of 4 × 102 cells/well
in 96-well cluster plates (Falcon, Becton-Dickinson, NJ,
USA). At 60% conﬂuence, cells were committed to dif-
ferentiate into adipocytes as previously described. Cells
were treated with increasing concentrations of FTI-277
(5–10μM) or with vehicle alone. Cell viability was as-
sessed using MTS Formazan before induction (time 0) and
48–72 hours after diﬀerentiation was induced. MTS For-
mazan assesses mitochondrial function by the ability of vi-
able cells to convert soluble 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTS) into an insoluble
dark blue Formazan reaction product measured photomet-
r i c a l l ya sp r e v i o u s l yd e s c r i b e d[ 18]. A stock solution of MTS
was dissolved in PBS at a concentration of 5mg/mL and
was added in a 1 : 10 ratio (MTS/DMEM) to each well in-
cubated at 37
◦C for 4 hours and the optical density de-
termined at a wavelength of 570–630nm on a microplate
reader model 3550 (Biorad, Hercules, Calif, USA). In pre-
liminary experiments, the absorbance was found to be di-
rectly proportional to the number of cells over a wide range
(2×102−5×104 cells/well). The percent survival was deﬁned
as [(experimentalabsorbance− blankabsorbance)/controlabsorbance−
blankabsorbance)] × 100, where the controlabsorbance is the op-
tical density obtained for 1 × 104 cells/well (number of cells
plated at the start of the experiment), and blankabsorbance is
the optical density determined in wells containing medium
and MTS alone.
Westernblotanalysis
MSCs were treated as previously described and then lysed in
20mM tris-HCl, pH 7, 5, 200mM DTT, 200mM KCl, 0.5ml
glycerol and protease inhibitor tablets (Roche Diagnostics
Canada, Laval, QC, Canada), freeze-thawed 3 times in a dry
ice-ethanol bath and centrifuged at 11,500 rcf for 15 minutes
to remove insoluble material. Lysates were dissolved in SDS
electrophoresis buﬀer (Bio-Rad, Hercules, Calif, USA) and
proteins separated on SDS-polyacrylamide gels and subse-
quently electrotransfered to polyvinylidene diﬂuoride mem-
branes. After membrane blocking with PBS containing 0.1%Daniel Rivas et al. 3
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Figure 1: Eﬀect of FTI-277on adipogenesis: human MSCs were committed to diﬀerentiate into adipocytes and treated for three weeks with
either FTI-277 (5μM) (b, d, f, and h) or vehicle alone (a, c, e, and g). At timed intervals (week 1 (a and b), week 2 (c and d), and week 3 (e
and f)), cells were ﬁxed, stained with oil red o, and counterstained with hematoxylin to assess adipocyte diﬀerentiation. Lower magniﬁcation
(10×) shows higher amount of fat droplets (red) and diﬀerentiated adipocytes in untreated cells at all time points (a, c, and e) as compared
with FTI-277-treated cells (b, d, and f). At higher magniﬁcation (100 ×), the amount and distribution of fat droplets is highly aﬀected
by treatment (h) where lipid droplets (red) are unable to reach conﬂuence as compared with untreated cells (g). Note the changes in the
cytoplasm after treatment (h) including vacuolization, irregular nuclei, and “mega” cytoplasm.4 PPAR Research
(a) (b)
Figure 2: Nuclear changes in diﬀerentiating MSCs after inhibition of protein farnesylation: cells were plated and induced to diﬀerentiate as
previously described. At week 2 of diﬀerentiation, cells were ﬁxed and stained using propidium iodide to identify nuclear changes (blebbing
and vacuolization). The ﬁgure shows the changes in nuclear morphology compatible with blebbing (white arrows) in most of the cells after
treatment with FTI-277 (5μM) (b). In contrast, untreated cells (a) showed fewer changes compatible with blebbing. Morphologically, cells
treatedwithFTI-277showedsmallernucleithanAIM-treatedcells.Photomicrographsweretakenat ×100magniﬁcationandrepresentthree
diﬀerent experiments.
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Figure 3:EﬀectofFTI-277onsurvivalofadipogenicdiﬀerentiating
MSCs: MSCs were plated 96-well plates and induced to diﬀerentiate
into adipocytes. Cells were treated with either FTI-277 (5–10μM)
or vehicle alone. After 24 and 48 hours, cell survival was assessed by
MTS Formazan as described in methods. There was no diﬀerence
between treated and nontreated cells at both time intervals. This
experiment was repeated three times.
Tween 20 and 10% non-fat dry milk, membranes were in-
cubated overnight at 4◦C using an antibody directed against
prelamin A (which crossreacts with lamin C), PPARγ,s t e r o l
regulatory element binding protein 1 (SREBP-1), lamin B,
and the chaperon protein HDJ-2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif, USA). The bound antibodies were
detected with the corresponding secondary antibodies con-
jugated with horseradish peroxidase (HRP). Blots were de-
veloped by enhanced chemiluminescence using Lumi-GLO
reagents (Kirkegoard & Perry, Gaithensburg, Mass, USA).
PPARγ activitymeasurement
DNA binding PPARγ activity was determined using the
ELISA-based PPARγ activation TransAM kit (Active Motif,
Rixensart, Belgium) as previously described [16]. The Trans-
AM PPAR-Kit contains a 96-well plate on which an oligonu-
cleotide containing a peroxisome proliferator response el-
ement (PPRE) (5 -AACTAGGTCAAAGGTCA-3 )h a sb e e n
immobilized. PPAR-contained in nuclear extract speciﬁcally
binds to this oligonucleotide. The primary antibody used in
the Trans-AM PPAR-Kit recognizes an accessible epitope on
PPAR-protein upon DNA binding. Addition of a secondary
horseradishperoxidase(HRP)-conjugatedantibodyprovides
a sensitive colorimetric readout easily quantiﬁed by spec-
trophotometry(450nm).ToquantifyPPAR-activation,20μg
of nuclear extract was measured using the Trans-AM PPAR
Kit according to the manufacturer’s instructions (Active Mo-
tif, Carlsbad, Calif, USA).
Statisticalanalysis
All results are expressed as mean ± standard error of the me-
dian(SEM)of3replicatedeterminations. Statisticalcompar-
isons are based on oneway analysis of variance (ANOVA) for
diﬀerenttimeintervalsorStudent’st-test.Aprobabilityvalue
of P < .05 was considered signiﬁcant.
3. RESULTS AND DISCUSSION
The progression of MSCs diﬀerentiation entails the up and
down regulation of multiple genes that will induce a change
i nc e l lp h e n o t y p ea sw e l la sc e l lf u n c t i o n[ 19]. This pro-
cess has been widely described and involves a three-week
exposure to diﬀerentiation media in which cells exposed
to insulin-containing adipogenesis induction media become
preadipocytes at week 2 and mature adipocytes at week 3
[20, 21]. The widely reported gene changes, occurring both
in vitro [22] and in vivo [19], have provided to the ﬁeld of
bone research an armamentarium to potential therapeutic
targets for senile osteoporosis [8, 20].
With aging, there is a predominant adipogenic diﬀeren-
tiation of bone marrow MSCs which is mostly associated to
high expression of PPARγ2[ 23, 24]. This factor determines
the commitment of MSCs into adipocytes at the expense ofDaniel Rivas et al. 5
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Figure 4: Eﬀect of FTI-277 on protein farnesylation and transcription factors for adipogenesis in diﬀerentiating MSCs: human MSCs were
plated in 6-well plates as previously described. After conﬂuence, media were replaced with AIM with FTI-277 (5 and 10μM) or vehicle
alone. Media were replaced every three days for three weeks. Nuclear extracts were obtained at weeks 1, 2, and 3 of diﬀerentiation and treated
as described in Materials and Methods. Membranes were incubated overnight at 4◦C using an antibody directed against either prelamin
A, HDJ-2, PPARγ, SREBP-1, and lamin B1. The bound antibodies were detected with the corresponding secondary antibodies conjugated
with horseradish peroxidase. Blots were developed by enhanced chemiluminescence using Perkin-Elmer reagents. Treatment with increasing
doses of FTI-277 induced an increase in both, prelamin A and unfarnesylated HDJ-2 expression (second upper band) suggesting that FTI-
277 was eﬀective on inhibiting farnesylation in this model of MSCs diﬀerentiation. Although a lower expression of both prelamin A and
HDJ-2 at week 3 of diﬀerentiation was found, the presence of an upper band in the treated cells suggests that inhibition of farnesylation by
FTI-277 was still eﬀective. Furthermore, inhibition of farnesylation correlates with lower levels of PPARγ. Finally, at weeks 1 and 2, a sharp
SREBP-1 68-kDa band (mature) correlates with higher levels of prelamin A expression whereas the 125-kDa precursor proteins is much
less intensely stained. These results suggest that inhibition of farnesylation aﬀects adipogenesis due to reduced expression of PPARγ which
correlate with higher levels of mature SREBP-1. Membranes were stripped and immunoblotted for lamin B1 levels to demonstrate equal
loading of proteins. The images are representative of three diﬀerent experiments.
theirdiﬀerentiationintoosteoblastwithasubsequentdecline
in bone formation [5, 8].
Overall, although there is a correlation between aging
and the transcription factors for bone marrow adipogenesis
[23], the link between them and the wholesome aging pro-
cess remains unclear.
Protein farnesylation is an essential step required for the
activation of several proteins involved in adipogenesis (i.e.,
GLUT-4, CREB, p21) [11]. Farnesylation is activated by a
protein farnesyltransferase (FTase) which adds a 15-carbon
farnesyl group to the cystein found within the CaaX motif
[25, 26]. This addition will induce the activation of multiple
proteins such as p21, HDJ-2, and lamins (A/C and B) [26].
Protein farnesylation could be inhibited using inhibitors of
FTase.
In the case of fat, insulin-stimulated prenylation of the
Ras family GTPases triggers the intrinsic cascade of adipo-
genesis [11]. This eﬀect is inhibited by FTI-277 in subcu-
t a n e o u sf a tc e l l st h u sa ﬀecting adipocyte diﬀerentiation of
preadipocytes [11, 15]. In contrast, the eﬀect of inhibition
of protein farnesylation in human MSCs committed to dif-
ferentiate into adipocytes remains unknown.
Among the proteins that require farnesylation to be acti-
vated, lamin A seems to play an important role in adipogenic
diﬀerentiation of MSCs. In fact, two studies have found
changesinlaminAexpressioninnormalmodelsofadipocyte
diﬀerentiation[27,28].Theﬁrstoneidentiﬁedlaminexpres-
sion in human adipose cells both in relation to anatomical
site and diﬀerentiation state ﬁnding that lamin A and B1, but
not B2, were expressed in mature human adipocytes whereas
preadipocytes expressed all four lamins [27]. A second study
looked at proteomic changes in adipocyte diﬀerentiation of
cells obtained from subcutaneous fat. Amongst the 170 pro-
tein features found in their study at day 9 of diﬀerentiation,
lamin A expression was included in the group of proteins
of the cytoskeleton with >3-fold reduction in its expression
[28].
Recent evidence looking at the role of lamins in adipo-
genesis has demonstrated that overexpression of lamin A in-
hibits adipogenic diﬀerentiation of 3T3 preadipocytes [12].6 PPAR Research
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Figure 5: Eﬀect of FTI-277 on PPARγ2a c t i vi t y:P P A R γ DNA bind-
ing activity was determined using ELISA-based PPARγ activation
kit and quantiﬁed by colorimetry. The levels of activity after treat-
ment with either AIM or AIM + FTI-277 (5–10μM) are shown.
Both dosages (5 and 10μM) signiﬁcantly reduced the activity of the
PPARγ complex in the nuclei. Values are mean ± SEM of 6 wells per
group in three independent experiments; ∗P < .01 versus matched
untreated cells.
This eﬀect was associated with inhibition of expression of
PPARγ2. In contrast, ﬁbroblasts obtained from mice lack-
ing lamin A showed higher potential to diﬀerentiate into
adipocytes. This evidence suggests that a reduction in lamin
A expression, which may happen with aging, would facilitate
the diﬀerentiation of MSCs into adipocytes.
Indeed, Young et al [25] have suggested that neither the
presence nor the absence of lamin A explains by itself the
physiologic role of lamin A in cell function and diﬀeren-
tiation. They demonstrated that lamin A could be negligi-
ble without aﬀecting cell function and diﬀerentiation [25].
Therefore, they propose that it is farnesylation and not lamin
A itself that could be important for disease pathogenesis.
In fact, both the absence of lamin A and the presence of
high levels of prelamin A seem to play opposing roles in adi-
pogenesis in several models of subcutaneous fat. Total ab-
sence of lamin A would stimulate adipogenesis [12]w h e r e a s
increased levels of prelamin A due to lack of farnesylation
inhibit adipogenesis through to the inhibition of PPARγ ac-
tivity [15].
Since subcutaneous and bone marrow fat could have sig-
niﬁcant physiological diﬀerences, in this study we decided to
test if inhibition of lamin A farnesylation has similar eﬀect
on human MSCs than the eﬀect seen in subcutaneous fat.
Diﬀerentiating MSCs were treated with an inhibitor of
protein farnesylation and the changes in their phenotype
and capacity to produce fat droplets assessed. As shown in
Figure 1, cells treated with FTI-277 showed changes in their
phenotype which include cytoplasm vacuolization, big nu-
clei, and decreased capacity to produce fat. Furthermore,
in agreement with previous reports on nuclear changes in-
ducedbylackoflaminAactivity,treatedcellsshowednuclear
changes compatible with nuclear blebbing and vacuolization
(see Figure 2)[ 18]. These changes did not have an eﬀect of
cell survival (see Figure 3).
To test if in eﬀect there was an inhibition in protein far-
nesylation, we assessed the expression of two proteins that
require farnesylation to be activated, lamin A and the chap-
eron protein HDJ-2. These two proteins are considered as
key markers of eﬀective inhibition of farnesylation [29]. As
shown in Figure 4, the presence of a double upper band
demonstrates the presence of prelamin A and unfarnesylated
HDJ-2 probing that FTI-277 inhibits farnesylation in this
modelinadose-dependentmanner.Thiseﬀectwasmoresig-
niﬁcant at week 1 and 2 of diﬀerentiation suggesting that the
eﬀect was more signiﬁcant during the preadipocyte stages.
However, although there is a reduction in both HDJ-2 and
p r e l a m i nAa tw e e k3o fd i ﬀerentiation, the double upper
band remains visible (see Figure 4).
Furthermore, we were interested in looking at the eﬀect
that inhibition of farnesylation has on PPARγ2 expression
and activity. A previous study using subcutaneous fat has
demonstratedthataccumulationofprelaminAinducedare-
duction in the levels of PPARγ expression [15]. In agreement
with their results, our study using human MSCs shows a re-
duction in the levels of PPARγ expression (see Figure 4)a t
all time intervals (weeks 1, 2 and 3). Furthermore, at weeks
1 and 2, the lower expression of PPARγ correlates with a sig-
niﬁcantly increased proportion of mature SREBP-1. The fact
that a higher proportion of mature SREBP-1 is found in FTI-
treated cells is also in agreement with previous reports which
suggest that sequestration of SREBP-1 by prelamin A has an
inhibitory eﬀect on PPARγ activity [15, 30]. This eﬀect was
predominantly found during the preadipocyte stages.
Finally, from a mechanistic approach, we looked at the
PPARγ2 nuclear complex activity in order to identify if pro-
tein farnesylation is required for eﬀective activation of this
complex. We found that treatment with FTI-277 aﬀects the
PPARγ2 nuclear complex in a dose-dependent manner (see
Figure 5).
Overall, in this model of human MSCs diﬀerentiation,
we have found that inhibition of farnesylation has an eﬀect
onadipogenesissimultaneouslyaﬀectingPPARγ2expression
and activity more markedly during the preadipocyte stages
of diﬀerentiation (week 1 and 2). A potential limitation of
our study is that pharmacological inhibition of farnesylation
could aﬀect many of the proteins that are required in adipo-
genesis. Therefore, further studies looking at farnesyltrans-
ferase knockdown in this model should be pursued.
In summary, our results outline the role of protein farne-
sylation in bone marrow adipogenesis and more speciﬁcally
in the activation of PPARγ in a model of insulin-induced
bone marrow adipogenesis.
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